<DOC>
	<DOCNO>NCT01290523</DOCNO>
	<brief_summary>This prospective pilot study document clinical experience 30 patient unresectable hepatocellular carcinoma undergo liver-directed therapy Yttrium-90 glass microspheres ( TheraSphereÂ® ) .</brief_summary>
	<brief_title>Yttrium-90 Radioembolization With Glass Microspheres ( TheraSphere ) Patients With Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Methamphetamine</mesh_term>
	<criteria>Diagnosis hepatocellular carcinoma liverdominant disease . Diagnosis may make histo cytopathology , clinical imaging criterion . The cancer unresectable . All patient must chemotherapeutic regimen 30 day prior 30 day TheraSphere treatment . Eastern Cooperative Oncology Group ( ECOG ) performance status 02 . Age 18 year old . Able understand inform consent . Evidence potential delivery great 16.5 mCi ( 30 Gy absorb dose ) radiation lung either : single TheraSphere administration ; cumulative delivery radiation lung great 50 Gy multiple treatment . Evidence detectable Tc99m macroaggregated albumin flow stomach duodenum , application establish angiographic technique stop flow . Previous radiation therapy lung and/or upper abdomen Pregnancy Symptomatic lung disease . Significant extrahepatic disease represent imminent lifethreatening outcome . Active uncontrolled infection Any pretreatment laboratory finding within 30 day treatment demonstrating : Aspartate alanine aminotransferase level great 5 time upper normal limit . Serum bilirubin great 2 mg/dl Infiltrative tumor image Tumor volume great 70 % liver volume Tumor volume great 50 % liver volume serum albumin level le 3 mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>